Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Arvinas Inc. (ARVN) Insider Trading Activity
Healthcare • Biotechnology • 445 employees
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Total Value
-$771,601.84
Total Shares
290,606
Average Trade Value
-$55,114.42
Most Active Insider
Houston John G
Total Activity: $523,881
Largest Single Transaction
$438,582
by Houston John G on Feb 24, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President and CEO
Director, Officer
|
Feb 24, 2025 | 26,184 | $438,582 | 1,162,634 (-2.3%) | Sale | |
|
President, Rd
Officer
|
Feb 24, 2025 | 1,664 | $27,539 | 159,121 (-1.0%) | Sale | |
|
Chief Scientific Officer
Officer
|
Feb 24, 2025 | 3,061 | $51,272 | 98,377 (-3.1%) | Sale | |
|
Chief Accounting Officer
Officer
|
Feb 24, 2025 | 1,214 | $20,335 | 18,863 (-6.4%) | Sale | |
|
President, Rd
Officer
|
Feb 24, 2025 | 7,356 | $123,213 | 160,785 (-4.6%) | Sale | |
|
President and CEO
Director, Officer
|
Feb 24, 2025 | 5,154 | $85,299 | 1,157,480 (-0.4%) | Sale | |
|
Chief Scientific Officer
Officer
|
Feb 24, 2025 | 1,146 | $18,966 | 97,231 (-1.2%) | Sale | |
|
Chief Scientific Officer
Officer
|
Feb 13, 2025 | 49,092 | $0 | 100,944 (+48.6%) | Grant | |
|
President and CEO
Director, Officer
|
Feb 13, 2025 | 152,000 | $0 | 1,188,681 (+12.8%) | Grant | |
|
Chief Scientific Officer
Officer
|
Feb 13, 2025 | 20,619 | $0 | 168,141 (+12.3%) | Grant | |
|
Chief Medical Officer
Officer
|
Feb 13, 2025 | 55,229 | $0 | 118,681 (+46.5%) | Grant | |
|
Chief Financial Officer
Officer
|
Feb 13, 2025 | 49,092 | $0 | 110,501 (+44.4%) | Grant | |
|
Chief Accounting Officer
Officer
|
Feb 13, 2025 | 10,584 | $0 | 18,624 (+56.8%) | Grant | |
|
Chief Accounting Officer
Officer
|
Nov 7, 2024 | 231 | $6,396 | 8,040 (-2.9%) | Sale |